Publications

Publications

FILTER
This page contains links to basic science and clinical research published on UCB medicines and disease areas of focus. The information is limited to products that have been approved for use by the U.S. Food and Drug Administration (FDA) and may contain information that is not part of the FDA-approved Prescribing Information (eg, doses, uses, devices, populations). UCB, Inc. does not recommend or endorse the use of its products in a manner not consistent with the approved Prescribing Information. Please see the Full Prescribing Information for each product when making clinical decisions.
Select product(s):
Select topic(s):
Phase:
phase 3

BIMZELX® (bimekizumab-bkzx)

Plaque Psoriasis

Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY): A multicentre, double-blind, placebo-controlled, randomised trial.

Kenneth B. Gordon, Peter Foley, James G. Krueger, Andreas Pinter, Kristian Reich, Ronald Vender, Veerle Vanvoorden, Cynthia Madden, Katy White, Christopher Cioffi, Andrew Blauvelt 2021
phase 3

BIMZELX® (bimekizumab-bkzx)

Plaque Psoriasis

Bimekizumab versus adalimumab in plaque psoriasis.

Richard B. Warren, Andrew Blauvelt, Jerry Bagel, Kim A. Papp, Paul Yamauchi, April Armstrong, Richard G. Langley, Veerle Vanvoorden, Dirk De Cuyper, Christopher Cioffi, Luke Peterson, Nancy Cross, Kristian Reich 2021
phase 2

BIMZELX® (bimekizumab-bkzx)

Plaque Psoriasis

Bimekizumab for patients with moderate to severe plaque psoriasis: 60-week results from BE ABLE 2, a randomized, double-blinded, placebo-controlled, phase 2b extension study.

Andrew Blauvelt, James Krueger, Steven Feldman, Yoshinori Umezawa, Nancy Cross, Cynthia Madden, Maggie Wang, Christopher Cioffi, Jose Manuel Lopez Pinto 2020
phase 3

CIMZIA® (certolizumab pegol)

Non-radiographic Axial Spondyloarthritis

A 52-week randomized placebo-controlled trial of certolizumab pegol in nonradiographic axial spondyloarthritis. 

Deodhar A, Gensler L, Kay J, et al. 2019
phase 3

CIMZIA® (certolizumab pegol)

Plaque Psoriasis

Certolizumab pegol for the treatment of chronic plaque psoriasis: results through 48 weeks from two phase 3, multicenter, randomized, double-blinded, placebo-controlled studies (CIMPASI-1 and CIMPASI-2). 

Gottlieb A, Blauvelt A, Diamant T, et al. 2018
phase 2

BIMZELX® (bimekizumab-bkzx)

Plaque Psoriasis

Dual neutralization of both interleukin 17A and interleukin 17F with bimekizumab in patients with psoriasis: Results from BE ABLE 1, a 12-week randomized, double-blinded, placebo-controlled phase 2b trial.

James Krueger, Steven Feldman, Yoshinori Umezawa, Jose Manuel Lopez Pinto, Nancy Cross, Luke Peterson, Christopher Cioffi, Andrew Blauvelt 2018
phase 3

CIMZIA® (certolizumab pegol)

Ankylosing Spondylitis, Non-radiographic Axial Spondyloarthritis

Limited radiographic progression and sustained reductions in MRI inflammation in patients with axial spondyloarthritis: 4-year imaging outcomes from the RAPID-axSpA phase III randomised trial. 

van der Heijde D, Baraliakos X, Hermann K-G, et al. 2018
phase 3

CIMZIA® (certolizumab pegol)

Plaque Psoriasis

Certolizumab pegol for the treatment of chronic plaque psoriasis: Results through 48 weeks of a phase 3, multicenter, randomized, double-blind, etanercept- and placebo-controlled study. 

Lebwohl M, Blauvelt A, Paul C, et al. 2018
phase 4

CIMZIA® (certolizumab pegol)

Women's Health

Lack of placental transfer of certolizumab pegol during pregnancy: results from CRIB, a prospective, postmarketing, pharmacokinetic study. 

Mariette X, Förger F, Abraham B, et al. 2018
phase 3

CIMZIA® (certolizumab pegol)

Psoriatic Arthritis

4-year results from the RAPID-PsA phase 3 randomised placebo-controlled trial of certolizumab pegol in psoriatic arthritis. 

van der Heijde D, Deodhar A, FitzGerald O, et al. 2018